Efficacy and Safety Study of Jaktinib in Subjects With Active Ankylosing Spondylitis(AS)
Status:
Not yet recruiting
Trial end date:
2025-07-01
Target enrollment:
Participant gender:
Summary
This is a Phase 3, multicenter, randomized, double-blind, placebo-controlled, efficacy and
safety study of Jaktinib in subjects with active Ankylosing Spondylitis(AS).